Skip to main content
Equibles

ATHE · Alterity Therapeutics Ltd

Track ATHE — free

Use ATHE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATHE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.05 -0.06 (-1.46%) At close · Sep 11
Rebalance outlook locked
Market Cap
$73.74M
Shares
18.21M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.05 Open$4.15 Day$4.05–4.33 52W close$2.92–5.89 Avg vol 30d16K Short int31K · 0.2% float · 1.4d Short vol57% Last earningsDec 31, 2020 DataJan 2023–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Jan 9, 2023; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+88.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-97.6%
Year over year · fewer shares
Price change (1Y)
-18.0%
Trailing year
Short interest
0.2%
Latest settlement · 1.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg −14%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 38%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −14%
trailing
6-month return +23%
trailing
YTD return +31%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +6 funds added
Insider flow Accumulating
Net +$23.8K over 90 days · 0% sells
Short interest Rising
0.17% of float · ▲ +27.0% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
21 holders — near 3-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 65%
annualized · 1-yr
Max drawdown −42%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
−14% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
38% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +6 funds added
Insider flow Accumulating
Net +$23.8K over 90 days · 0% sells
Short interest Rising
0.17% of float · ▲ +27.0% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
21 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 38% Range high $6
vs 200-day avg +1% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATHE
Alterity Therapeutics Ltd
this stock
$73.74M +31.5% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
21
% held
2.2%
Net QoQ
+73.6K sh
Top holder
Twin Lakes Capital Manage…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
31.5K
Days to cover
1.4d
Change
+6.7K sh
View
Short Volume
Short vol %
57%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
10.0K
Value
$46.1K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
74.8%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$23.8K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 8, 2026
This year
69
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jan 9, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ATHE -10.4% -13.8% +23.1% -9.8% +31.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -9.3% -12.1% +5.3% -9.4% +19.4%
Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 4 filings 4 filers Visit website Investor relations